Sansure Biotech Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Public

  • Employees
  • 2,006

Employees

  • Stock Symbol
  • 688289

Stock Symbol

  • Investments
  • 6

  • Share Price
  • $2.93
  • (As of Friday Closing)

Sansure Biotech General Information

Description

Sansure Biotech Inc is engaged in production and sales of diagnostic reagents and instruments. The company produces Class I medical devices, Class II medical devices, Class III medical devices, general instruments and meters, medical raw materials, medical laboratory equipment and appliances, and medical accessories.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • No. 680, Lusong Road
  • High-tech Industrial Development Zone
  • Changsha, Hunan 410205
  • China
+86 0731
Primary Industry
Biotechnology
Other Industries
Laboratory Services (Healthcare)
Diagnostic Equipment
Stock Exchange
SHG
Vertical(s)
Corporate Office
  • No. 680, Lusong Road
  • High-tech Industrial Development Zone
  • Changsha, Hunan 410205
  • China
+86 0731

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sansure Biotech Stock Performance

As of 07-Feb-2025, Sansure Biotech’s stock price is $2.93. Its current market cap is $1.7B with 579M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.93 $2.85 $2.30 - $3.64 $1.7B 579M 8.62M $0.06

Sansure Biotech Financials Summary

As of 30-Sep-2024, Sansure Biotech has a trailing 12-month revenue of $196M.

In Thousands,
USD
TTM 30-Sep-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 1,215,815 963,288 1,106,496 2,947,858
Revenue 196,035 142,351 957,802 699,161
EBITDA 25,137 67,154 350,244 408,613
Net Income 36,141 51,410 287,592 347,324
Total Assets 1,222,309 1,192,648 1,329,666 1,112,372
Total Debt 62,108 5,405 4,038 2,337
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Sansure Biotech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Sansure Biotech‘s full profile, request access.

Request a free trial

Sansure Biotech Patents

Sansure Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-D1023334-S1 Automatic nucleic acid detection analyzer Active 21-Feb-2022
US-20240141417-A1 Molecular detection system and detection method thereof Pending 18-Feb-2022
EP-4441241-A1 Molecular detection system and detection method thereof Pending 18-Feb-2022
EP-4326909-A1 Composition, kit, method for detecting hiv-1 and use thereof Pending 27-Jan-2022
US-20240368714-A1 Composition, kit, method for detecting hiv-1 and use thereof Pending 27-Jan-2022 C12Q1/703
To view Sansure Biotech’s complete patent history, request access »

Sansure Biotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sansure Biotech Investments (6)

Sansure Biotech’s most recent deal was a Early Stage VC with ShengWeiKunTeng for . The deal was made on 23-Dec-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ShengWeiKunTeng 23-Dec-2024 Early Stage VC Diagnostic Equipment
Hunan Sanway SepSMART 05-Apr-2024 Joint Venture Laboratory Services (Healthcare)
ShengWeiKunTeng 30-Oct-2023 Seed Round Diagnostic Equipment
Singlera Genomics 08-Jun-2022 Later Stage VC Diagnostic Equipment
GeneMind 15-Sep-2021 Later Stage VC Diagnostic Equipment
You’re viewing 5 of 6 investments. Get the full list »

Sansure Biotech ESG

Risk Overview

Risk Rating

Updated August, 12, 2024

28.45 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,120

Rank

Percentile

Healthcare

Industry

of 587

Rank

Percentile

Medical Devices

Subindustry

of 199

Rank

Percentile

To view Sansure Biotech’s complete esg history, request access »

Sansure Biotech FAQs

  • When was Sansure Biotech founded?

    Sansure Biotech was founded in 2008.

  • Where is Sansure Biotech headquartered?

    Sansure Biotech is headquartered in Changsha, China.

  • What is the size of Sansure Biotech?

    Sansure Biotech has 2,006 total employees.

  • What industry is Sansure Biotech in?

    Sansure Biotech’s primary industry is Biotechnology.

  • Is Sansure Biotech a private or public company?

    Sansure Biotech is a Public company.

  • What is Sansure Biotech’s stock symbol?

    The ticker symbol for Sansure Biotech is 688289.

  • What is the current stock price of Sansure Biotech?

    As of 07-Feb-2025 the stock price of Sansure Biotech is $2.93.

  • What is the current market cap of Sansure Biotech?

    The current market capitalization of Sansure Biotech is $1.7B.

  • What is Sansure Biotech’s current revenue?

    The trailing twelve month revenue for Sansure Biotech is $196M.

  • What is Sansure Biotech’s annual earnings per share (EPS)?

    Sansure Biotech’s EPS for 12 months was $0.06.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »